FDA Launches PreCheck Program to Accelerate Domestic Drug Manufacturing and Bolster U.S. Supply Chain Resilience

Spread the Message

Read Time:4 Minute, 56 Second

Washington, D.C. – February 2, 2026 – The U.S. Food and Drug Administration (FDA) has begun accepting applications for its innovative PreCheck pilot program, a key initiative to ramp up domestic pharmaceutical manufacturing and address persistent drug shortages threatening public health. Announced in response to President Donald Trump’s May 2025 Executive Order 14293, the program opened on February 1, 2026, targeting new U.S.-based facilities producing critical medications to enhance national security and supply chain stability.

Program Details and Timeline

The FDA PreCheck program employs a two-phase structure designed to provide regulatory predictability and streamline facility assessments before product applications are submitted. In Phase 1, the Facility Readiness Phase, selected manufacturers receive early technical advice, pre-operational reviews, and support for a facility-specific Drug Master File to evaluate site elements ahead of operations.

Phase 2, the Application Submission Phase, builds on this foundation with pre-submission meetings and inspections to resolve issues and expedite reviews of manufacturing information in drug applications. The FDA will select an initial cohort of facilities in 2026 based on criteria including alignment with national priorities, such as products manufactured (e.g., those addressing shortages or on the Essential Medicines List), development phase, market timeline, and innovative designs. Priority goes to sites producing critical drugs like sterile injectables.

This voluntary pilot stems from the executive order aimed at eliminating unnecessary regulations and restoring a robust U.S. manufacturing base, where currently only 11% of active pharmaceutical ingredients (APIs) are produced domestically and over half of distributed pharmaceuticals come from overseas.

The Drug Shortage Crisis Driving Change

Drug shortages have plagued the U.S. healthcare system for years, peaking at 323 active shortages in early 2024—the highest since tracking began in 2001—and remaining around 253-270 into 2025-2026. Generic sterile injectables, chemotherapy drugs, and antibiotics are hit hardest, with over half of shortages lasting more than two years and affecting roughly 500,000 people per incident, disproportionately impacting seniors.

These disruptions, exacerbated by global events like the COVID-19 pandemic, geopolitical tensions, and quality issues at foreign facilities (e.g., a 2022 cisplatin shortage from an Indian plant), underscore vulnerabilities in overseas-dependent supply chains. Over 90% of U.S. prescriptions are generics, many reliant on APIs from China and India, making onshoring a strategic imperative for resilience.

Healthcare leaders applaud the move as a proactive step toward supply security. “PreCheck represents a welcome shift toward earlier, more collaborative FDA engagement, potentially cutting time-to-market for critical drugs and reducing shortage risks,” said Michael Kopcha, Director of the FDA’s Office of Pharmaceutical Quality, during a September 2025 stakeholder meeting.

Dr. Janet Woodcock, former FDA Center for Drug Evaluation and Research Director (not involved in PreCheck), noted in prior commentary on supply issues: “Streamlining domestic facility readiness is essential; it allows direct oversight, faster crisis response, and job creation while mitigating geopolitical risks.” Industry stakeholders at the meeting echoed this, praising decoupled reviews but calling for expansions like including contract manufacturing organizations (CMOs) and stronger incentives.

Onshoring could enhance quality compliance, as U.S. facilities face rigorous Good Manufacturing Practices (GMP) enforcement, unlike some overseas sites prone to contamination or inconsistencies.

Public Health Implications and Practical Benefits

For patients, fewer shortages mean reliable access to essentials like cancer treatments, antibiotics, and emergency injectables, potentially saving lives during surges (e.g., flu seasons or disasters). Healthcare providers gain agility in sourcing, reducing rationing and treatment delays.

Consumers might see indirect benefits like stabilized prices long-term, though initial onshoring costs could raise generic prices short-term due to higher U.S. labor and regulations—offset by reduced import tariffs and disruptions. Policymakers tie this to national security, prioritizing facilities for drugs on shortage lists or vital for public health preparedness.

The complementary FDA Commissioner’s National Priority Voucher Program, launched in June 2025, further accelerates reviews for critical drugs, promising decisions in 1-2 months versus 4-6.

Challenges, Limitations, and Balanced View

While promising, experts caution on hurdles. Building advanced U.S. facilities demands massive investment, with generics’ low margins deterring manufacturers unless incentives like tax credits expand. Proposed tariffs (50-200%) on imports could spike shortages if onshoring lags, hitting vulnerable injectables hardest.

Industry feedback highlights needs for clearer confidentiality, broader scope, and FDA-wide alignment to avoid bottlenecks. Critics argue over-reliance on pilots risks uneven implementation, and economic viability remains unproven without subsidies—echoing past efforts where 37% of approved generics never launched due to market barriers.

Skeptics like some LinkedIn analysts suggest bolder steps, such as waiving pre-approval inspections for domestic sites and 45-60 day approvals. Still, PreCheck’s focus on innovation and rapid timelines positions it as a pragmatic start.

Broader Context and Future Outlook

This initiative aligns with bipartisan supply chain reviews from Trump and Biden eras, responding to globalization’s pitfalls exposed by pandemics and trade wars. Globally, similar pushes in Europe emphasize resilience, but U.S. scale could lead if executed well.

For health-conscious readers, monitor FDA updates on selected facilities; diversified personal medicine cabinets and pharmacist discussions remain wise amid transitions. The program signals a healthier, more secure pharma future, but success hinges on execution and support.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: